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Systemic Administration of Human Adipose-Derived
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Over the last decade, it has been proved that mesenchymal stem cells (MSCs) elicit anti-inflammatory effects.
MSCs from adipose tissue (hASCs) differentiate into cells of the mesodermal lineage and transdifferentiate into
ectodermal-origin cells. Although there are various etiologies to chronic pain, one common feature is that painful
states are associated with increased inflammation. We believe in hASCs as a therapeutic tool also in pathologies
involving neuroinflammation and neuronal tissue damage. We have investigated the effect of hASCs injected in
a model of neuropathic pain [(mouse sciatic nerve chronic constriction injury (CCI)]. hASCs from 5 donors were
characterized, and no major differences were depicted. hASCs were cryopreserved and grown on demand.
About 1 · 106, 3 · 106, and 6 · 106 hASCs were intravenously injected into normal immunocompetent mice. No
mouse died, and no macroscopic toxicity or behavioral changes were observed, confirming the safety of hASCs.
hASCs, intravenously (i.v.) injected into C57BL/6 mice when the neuropathic pain was already established,
induced a significant reduction in mechanical allodynia and a complete reversion of thermal hyperalgesia in a
dose–response fashion, already 1 day after administration. Moreover, the hASCs effect can be boosted by
repeated administrations, allowing a prolonged therapeutic effect. Treatment decreased the level of the CCI-
induced proinflammatory cytokine interleukin (IL)-1b and activated the anti-inflammatory cytokine IL-10 in the
lesioned nerve. hASCs treatment also restored normal inducible nitric oxide synthase expression in the spinal
cord of CCI animals. Our data suggest that hASCs are worthy of further studies as an anti-inflammatory therapy
in the treatment of neuropathic pain or chronic inflammatory diseases.
Introduction
Mesenchymal stem cells (MSCs) are a heterogeneouspopulation that can be isolated from several tissues,
expanded in vitro, and purified by plastic adherence.
Adipose tissue is an attractive abundant source of MSCs
(ASCs, adipose-derived stromal/stem cells), which are able
to differentiate into cells of the mesodermal lineage such as
osteoblasts, adipocytes, chondrocytes, and myocytes [1–3],
and also to transdifferentiate into cells of the ectodermal
lineage [4–6]. In the last 10 years, the knowledge about their
features and their application potential in life science have
increased rapidly, and the interest in cell-based therapies
involving ASCs is also exponentially growing. Until recently,
ASCs have been applied in the regenerative medicine field,
since they are able to promote the regeneration of damaged
soft and hard tissues. We previously showed that ASCs are
not significantly affected by the donor’s age [7], and that the
stromal vascular fraction (SVF) from subcutaneous fat tissue
contains NGF + ASCs, precursor/progenitor cells that effi-
ciently differentiate toward osteogenic- and chondrogenic-
like cells [8], confirming this tissue as a source of agents
prone to regenerate various tissues.
Furthermore, ASCs, as other MSCs, are known to be im-
munomodulatory through the regulation of immune cells [9]
by mechanisms that include both direct cellular contact and
release of soluble factors such as trasforming growth factor-
b, interleukin (IL)-10, leukemia inhibitory factor (LIF), and
others [10]. It has been shown that ASCs reduce allogeneic
lymphocyte response by displaying potent immunosup-
pressive effects that could be mediated by LIF [11], and that
MSCs suppressed both effector T-cell and inflammatory re-
sponses. Gonzalez-Rey et al. [12] showed that human ASCs
produced IL-10 interacting with monocytes, and this cell–cell
contact also committed monocytes to produce high levels of
IL-10, suggesting that human ASCs (hASCs) indirectly sup-
press T-cell activation by increasing the production of IL-10
by antigen-presenting cells. Confirming their features, ASCs
1Dipartimento di Scienze Farmacologiche e Biomolecolari, Universita` degli Studi di Milano, Milano, Italy.
2Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Universita` degli Studi di Milano, Milano, Italy.
3I.R.C.C.S. Istituto Ortopedico Galeazzi, Milano, Italy.
STEM CELLS AND DEVELOPMENT
Volume 00, Number 00, 2013
 Mary Ann Liebert, Inc.
DOI: 10.1089/scd.2012.0398
1
have been introduced into clinical therapies for prevention or
reduction of graft-versus-host disease associated to allogenic
transplantation and for the treatment of autoimmune dis-
eases, despite an incomplete understanding of their mecha-
nism of action [13]. Animal studies clearly indicate the
therapeutic role of MSCs both in autoimmune diseases such
as autoimmune encephalomyelitis [14] and systemic lupus
erythematosus [15] and in diabetic polyneuropathy [16];
furthermore, some clinical trials have produced promising
results [17].
Hovewer, the safety and efficacy of allogeneic MSCs in
long-term studies remain still to be clarified although in
short-term experiments, both in animals and in humans, the
use of MSCs has been shown to be safe [18–20].
Neuropathic pain, consequent to iatrogenic (amputation,
cholecystectomy, etc), or traumatic injuries, tumors com-
pressing peripheral nerves, drugs, metabolic (diabetes) or
viral (Herpes Zoster, HIV) diseases, affects 1% of the popu-
lation, and it most frequently involves the peripheral nervous
system. Its treatment is still a complex issue, andwhatever the
cause, neuropathic pain is treated with antidepressant or
anticonvulsant drugs, transcutaneous electrical nerve stimu-
lation, and psychological/cognitive help. However, all these
treatments provide relief in a limited percentage of patients
(30%, ie, comparable to placebo) [21], before pain inevitably
reappears. A nonphysiological repair of the lesioned nerve
leading to the formation of neurinomas, altered nerve con-
duction, and spontaneous firing is considered one of the main
causes of the events underlying neuropathic pain. We and
others also demonstrated that a peripheral nerve lesion starts
a cascade of neuroinflammation-related events that may
maintain and worsen the original injury, participating in pain
generation and chronicization [22–24].
In this view, the use of MSCs, due to their immunomod-
ulatory effects on the neuroinflammatory cascade, could be a
valid approach to treat neuropathic pain. Musolino and Si-
niscalco directly injected into the nervous system, autologous
bone marrow stem cells (BMSCs) in rats, and human BMSCs
in mice, respectively [25,26]; however, although promising,
these approaches present several important drawbacks. In
the first instance, the isolation of MSCs from bone marrow is
not easy, and, even more important, the quantity of cells that
can be obtained is limited. In the second instance, the intra-
ventricular or intraganglional routes of administration are
both troublesome and difficult to apply safely. We previ-
ously showed that intravenous administration of murine
neural stem cells (NSCs) leads to a reduction of neuropathic
pain symptoms such as hyperalgesia and allodynia in a well-
established murine model of pain [sciatic nerve chronic
constriction injury (CCI)] [27], and that NSCs could modu-
late pro- and anti-inflammatory cytokines in the sciatic nerve
of CCI mice even when the pathology was already estab-
lished [27]. Moreover, the NSCs effect on pain symptoms and
cytokines preceded nerve repair and was maintained after
cells had disappeared from the lesion site, suggesting that
NSCs effects are largely due to microenvironmental changes
they might induce at the lesion site.
On these bases, we thought that hASCs could offer a more
suitable alternative, in consideration of their relevant im-
munomodulatory effects on the neuroinflammatory cascade
that plays an important role in the etiopathogenesis and
maintenance of this type of pain [22,28]. Moreover, they are
available in great amount, and if necessary, autologous cells
could be easily withdrawn.
Here, we describe the sustained and prolonged anti-
hyperalgesic effect of intravenously injected human ASCs in
a CCI preclinical model of neuropathic pain in immuno-
competent C57BL/6 mice.
Materials and Methods
In vitro characterization
Isolation and culture of hASCs. Subcutaneous adipose tis-
sues were obtained from 5 healthy female donors (age range
26–58 years/old) undergoing plastic surgery and after written
consent and Institutional Review Board (IBR) authorization
from Galeazzi Orthopaedic Institute, Milano, Italy. hASCs
were isolated as previously described [7]. Briefly, raw lipoas-
pirates (20–180mL) were enzymatically digested with 0.075%
type I collagenase at 37C, for 30min. The SVF was obtained
by centrifugation (1,200 g· 10min), filtered through a sterile
medication lint, and plated (105 cells/cm2) in a control me-
dium (CTRL) consisting of the Dulbecco’s modified Eagle’s
medium (DMEM; Sigma-Aldrich, Milan, Italy), supplemented
with 10% fetal bovine serum (FBS), 50U/mL penicillin, 50mg/
mL streptomycin, and 2mM l-glutamine (Sigma-Aldrich)
(cDMEM). Cells were cultured at a density of 104 cells/cm2 [7].
Fibroblast colony-forming unit (CFU-F) assay was performed
as follows: hASCs were plated in the DMEM supplemented
with 20% FBS, 50U/mL penicillin, 50mg/mL streptomycin,
and 2mM l-glutamine, in 6-well plates starting from 1,000
cells/well to 125 cells/well. Six days later, the medium was
replaced, and, at day 14, cells were fixed with 100% methanol
and stained with 0.5% crystal violet (Fluka, Buchs, Switzer-
land). The frequency of the CFU-F was established by scoring
individual colonies (consisting of at least 25 cells) with respect
to the number of seeded cells. hASCs at passages either 3 or 4
were frozen in a 10:1 ratio of FBS/dimethyl sulfoxide (Sigma-
Aldrich) and cryopreserved at - 80C or in liquid nitrogen
until required for the in vivo studies.
To assess the genetic stability, thawed hASCs were cul-
tured for additional 10 passages, and karyotyping was per-
formed (TOMA Advanced Biomedical, Busto Arsizio, Italy).
Cells were treated by 0.05mg/mL colcemid (Invitrogen,
Monza, Italy) for 1–2 h to block cell division in the meta-
phase, then harvested, and 50 metaphases in each sample
were analyzed. The chromosomes were then observed by
Q-banding by quinacrine [29].
Assesment of multidifferentiative potential of hASCs. At
passage 3, 104 cells/cm2 were induced to differentiate into the
adipogenic (cDMEM supplemented with 1mM dexametha-
sone, 10mg/mL insulin, 500mM 3-isobutyl-1-methyl-xanthine,
and 200mM indomethacin; Sigma-Aldrich [7]), osteogenic
(cDMEM with 10nM dexamethasone, 10mM glycerol-2-
phosphate, 150mM l-ascorbic acid-2-phosphate, and 10nM
cholecalciferol; Sigma-Aldrich [7]), myogenic (cDMEM plus
5% horse serum donor herd, 0.1mM dexamethasone, and
50mM hydrocortisone; Sigma-Aldrich [30]), and vascular en-
dothelial (DMEM, 2% insulin, transferrin, and selenium,
10ng/mL fibroblast growth factor-2 (FGF-2), 20 ng/mL in-
sulin-like growth factor-I (IGF-I), 0.2mg/mL hydrocortisone,
1mg/mL ascorbic acid, 0.5ng/mL vascular endothelial
growth factor (VEGF), 50U/mL penicillin, 50 mg/mL
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streptomycin, and 2mM l-glutamine; Sigma-Aldrich [31])
lineages.
Fourteen days later, adipogenic differentiation was eval-
uated in hASCs fixed in 10% neutral buffered formalin for 1 h
and stained with a fresh Oil Red O solution (2% weight/
volume Oil Red O in 60% isopropanol) for 15min [7].
Osteogenic markers such as alkaline phosphatase (ALP),
collagen production, and calcified extracellular matrix de-
position were analyzed after 14 and 21 days in culture,
respectively. To evaluate ALP enzymatic activity in differ-
entiated hASCs, both undifferentiated and differentiated
cells were lysed in 0.1% Triton X-100 and incubated at 37C
in the presence of 10mM p-nitrophenylphosphate in 100mM
diethanolamine and 0.5mM MgCl2, pH 10.5 [32]. Samples
were read at 405 nm with the Wallac Victor II plate reader,
and ALP activity was normalized with respect to the protein
concentration for each sample determined by the BCA Pro-
tein Assay (Pierce Biotechnology, Rockford, IL). Total colla-
gen production was determined in hASCs fixed for 1 h with
Bouin’s solution (Sigma-Aldrich) and then stained for 1 h
with 0.1% Sirius Red F3BA in picric acid [33]. To evaluate the
calcified extracellular matrix deposition, hASCs were fixed
1 h in ice-cold 70% ethanol, and then stained for 15min with
40mM Alizarin Red-S (pH 4.1) [34]. Washed and dried
samples were then incubated 20min at room temperature
with 10% w/v cetylpyridinium chloride in 0.1M phosphate
buffer (pH 7.0); the extracted matrix was read at 550 nm.
Animals and experimental protocol
All performed experiments were in accordance with the
Italian State and European regulations governing the care
and treatment of laboratory animals (permission No. 94/
2000A) and conformed to the guidelines for the study of pain
in awake animals established by the International Associa-
tion for the Study of Pain [35]. The experimental work was
previously reviewed by the Animal Care and Use Committee
of the University of Milan. Animals were kept on a 12-h
light–dark cycle with water and food ad libitum.
CCI model. Painful neuropathy was induced on C57BL/
6J male mice (20–25 g; Harlan, Italy). The CCI model origi-
nally described by Bennett and Xie [36] for rats was adapted
for mice as described in our previous studies [22,23,27].
Briefly, animals were anesthetized with sodium pentobarbi-
tal [60mg/kg, intraperitoneal (i.p.), 0.1mL/10 g], and under
a dissecting microscope, the right common sciatic nerve was
exposed at the level of the mid-thigh proximal to the trifur-
cation of the nerve; 3 ligatures (4/0 chromic silk; Ethicon)
were loosely tied around it, at about 0.5-mm spacing, until
they elicited a brief twitch in the respective hind, taking care
to preserve epineural circulation. Sham-operated animals
(sciatic exposure without ligation) were used as controls.
Thermal hyperalgesia and mechanical allodynia evalua-
tion. Thermal hyperalgesia was tested according to the
Hargreaves procedure [37], slightly modified by us for
mouse, using a plantar test apparatus (Ugo Basile, Comerio,
Italy). Briefly, mice were placed in smaller clear plexiglass
cubicles and allowed to acclimatize. A constant-intensity
radiant heat source (beam diameter 0.5 cm and intensity 20
I.R.) was aimed at the midplantar area of the hind paw. The
time, in seconds (s), from initial heat source activation until
paw withdrawal was recorded. Mechanical allodynia was
assessed using the dynamic plantar esthesiometer (Ugo Basile,
Comerio, Italy). Animals were placed in a test cage with awire
mesh floor, and the rigid tip of a von Frey filament (punctate
stimulus) was applied to the skin of the midplantar area of the
hind paw. The filament exerted an increasing force, ranging
up to 5 g in 20 s, starting below the threshold of detection and
increasing until the animal removed its paw. Withdrawal
threshold was expressed in grams. Withdrawal threshold of
ipsilateral and contralateral paws was measured 4 times, and
the value was the mean of the 4 evaluations. Measurements
were performed on both the ipsilateral and contralateral hind
paws of all mice by researchers blind to treatments.
Injection protocol. Cell administration was always per-
formed 7 days after CCI, when the pain hypersensitivity was
maximal. hASCs were mechanically dissociated to a single-cell
suspension in phosphate-buffered saline (PBS) with 2.5% hep-
arin and injected intravenously in the caudal vein to mice. The
cells were administered in the amount of 1·106 or 5·105/
200mL to CCI and sham mice. In one group of animals, 1·106
cells were injected for a second time 21 days after the first 1·106
cell treatment, while a group of mice that had received 5·105
cells was reinjected with the same amount of cells 14 days later.
Thermal hyperalgesia and mechanical allodynia were
evaluated in all mouse groups immediately before surgery
and at day 7 after surgery, before cell injection (time 0). The
subsequent evaluations were performed 24h and at days 3,
7, 14, 21, and 28 after the first hASCs administration.
Cytokine evaluation. Twenty-four hours, 3, and 7 days
after administration of 1· 106 and 5· 105 hASCs, mice were
anaesthetized with sodium pentobarbital (60mg/kg, i.p.,
0.1mL/10g), and under a dissecting microscope, the ipsi-
lateral sciatic nerve, proximal to the trifurcation (about 1 cm),
before the 3 ligatures in the CCI animals, was removed and
immediately frozen in liquid nitrogen and stored at - 80C
until the cytokine assay. Whole blood was collected 24 h and
7 days after hASCs administration by puncture of the tail
vein, centrifuged, and sera were stored at - 80C until mouse
and human IL-1b and IL-10 were tested.
The nerve samples were homogenized in 0.4mL of ice-cold
PBS containing a protease inhibitor cocktail (Sigma-
Aldrich) and centrifuged at 10,000 g for 15min, as previously
described [23,27]. The supernatant was used to measure
mouse IL-1b and mouse and human IL-10 levels and total
protein content (Lowry’s method). IL-1b and IL-10 protein
contents were determined by enzyme-linked immunosorbent
assay (ELISA) using ultrasensitive ELISA kits according to the
manufacturer’s instruction (mouse IL-1: R&D system Min-
neapolis, MN;mouse IL-10: BectonDickinson, San Diego, CA;
human IL-10 and IL-1b: Ebioscience, Prodotti Gianni, Milano
Italy). Cytokine concentrations were determined by interpo-
lation with standard curves assayed on individual plates and
normalized to the protein content in each sample.
Determination of spinal cord-induced nitric oxide synthase
by western blot analysis. Seven days after hASC treatment,
mice were anaesthetized with sodium pentobarbital (60mg/
kg, i.p., 0.1mL/10 g), and under a dissecting microscope, the
lumbar dorsal spinal cord at the L4–L6 level was removed
and immediately frozen.
To assess the level of induced nitric oxide synthase (iNOS)
dosage, tissues were defrosted at room temperature,
weighed, diluted (1:20 w/v) in a lysis buffer [50mM Tris–
HCl, pH 7.4, 150mM NaCl, 0.1% sodium dodecyl sulfate
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(SDS), 1% Igepal CA-630, 0.5% sodium deoxycholate, 0.02%
sodium azide, 1mM phenylmethylsulfonyl fluoride, and
10mM leupeptin], homogenized using an ultrasonic pro-
cessor homogenizer UP 50H (Dr. Hielscher, Gmbh, Berlin,
Germany) and centrifuged at 1,500 g at 4C for 10min. After
protein dosage, the supernatant was diluted in the Laemmli
buffer (0.3M Tris–HCl, pH 6.8, containing 10% SDS, 50%
glycerol, 5% dithiothreitol, and 0.05% bromophenol blue) to
obtain 40mg of proteins. The proteins were loaded onto a
7.5% SDS–polyacrylamide gel and then transferred onto a
nitrocellulose membrane (Schleicher and Schull, BAS 85)
with the semidry method for 90min at room temperature.
The membrane was blocked with 5% nonfat dry milk (Bio-
Rad, Milan, Italy) in Tris-buffered saline tween (TBST)
(20mM Tris base, pH 7.6, 137mM NaCl, and 0.1% Tween 20)
at room temperature for 2 h and then incubated with a pri-
mary polyclonal antibody directed against mouse iNOS
(Cayman Chemical, Ann Arbor, MI) diluted 1:1,000 in a
blocking solution, at 4C overnight. The nitrocellulose mem-
brane was also probed with a polyclonal anti-b actin antibody
(1:3,000; Cytoskeleton, Inc., Denver, CO) as a loading control.
Immunoreactive bands were analyzed using a computer-
based densitometry NIH (National Institute of Health) image
program. After washing in the TBST buffer, the blot was in-
cubated with a secondary antibody (anti-rabbit IgG, peroxi-
dase-linked F(ab¢)2 fragment, from Amersham Pharmacia
Biotech, Milan, Italy, 1:1,500 in 3% blocking solution) for 1 h at
room temperature. After washing in the TBST buffer, the blot
was detected with an enhanced chemiluminescence detection
kit (Roche Diagnostics, Monza, Italy). Gray levels, obtained
by densitometric analysis of immunoreactive bands, were
normalized on b-actin and expressed as the percentage of the
sham-operated mouse levels.
Statistical analysis
The data are expressed as mean– SEM. Statistical analyses
were performed using Student t-test or one-way ANOVA
followed by Tukey’s test. Differences were considered sig-
nificant at P< 0.05. All the statistical analyses were per-
formed using GraphPad 4 software (San Diego, CA).
Results
Features of hASCs populations
All the experiments were performed with 5 cellular pop-
ulations derived from female donors, between 26 and 58
years of age (mean – SEM: 37.6 – 5.5), and from different
anatomical regions (Table 1). Despite the mild variability, all
the populations form colonies (range 0.6%–4.3% of cells en-
dowed with clonogenic capacity); the average doubling time
during early passages was also not homogeneous, and in-
deed spans between 69.0 and 120.2 h. All the hASCs popu-
lations showed the peculiar human morphology (Fig. 1A)
both before and after freezing. For the in vivo experiments,
we used cryopreserved cells; to achieve the established
number of cells for the injections cells were usually split for 3
or 4 passages: 3 hASCs batches were cultured until passage 8
and the others till passage 7 (Table 1). The same populations
were then maintained until passage 10, and their genetic
stability during proliferation was analyzed by karyotyping.
An average of 50 metaphasic plates was analyzed for each
sample, and no numerical and structural chromosomal ab-
normalities were observed in any sample. Three represen-
tative karyotype images are shown in Fig. 1C.
To assess the hASCs multidifferentiative potentiality, cells
were induced for 2 weeks in the presence of stimuli for
osteogenic, adipogenic, myogenic, and endothelial differen-
tiation: the morphological changes peculiar of each differ-
entiation could be depicted already after 14 or 7 days of
culture, for adipogenic and osteogenic or myogenic and en-
dothelial differentiation, respectively, as shown in Fig. 1B.
hASCs were efficiently induced toward cells of the adipo-
genic lineage, as revealed by lipid vacuole formation (Table 1
and Fig 1B, D). Furthermore, osteogenic stimuli promoted
the secretion of collagen as shown in Fig. 1D, where differ-
entiated hASCs-4 have been shown, and an increase in both
ALP activity and calcified extracellular matrix deposition of
about 312.4% and 227.3%, respectively, compared to undif-
ferentiated cells (Fig. 1E, table and graph).
Conditions and survival rate of animals
injected with hASCs
To exclude a possible toxic effect of hASCs, increasing
doses of cells from 1· 106 to 6· 106 of human cells corre-
sponding to 40,000 and 240,000 cells/g of animal’s body
weight, were intravenously injected in not-immune-compro-
mised mice. The injected volume was always 200 mL, inde-
pendent on the number of cells. Single dose of either 1 · 106
or 3 · 106 cells was injected in 1 shot, whereas the highest
dose (6· 106) was administered in 2 identical shots. The an-
imals were observed twice a day. Independently on the cell
dose, no mouse died either immediately after the injection or
Table 1. Features of Human Adipose-Derived Stem Cell Populations Used for the CCI Model Treatment
Body DT
Differentiation
Cryopreservation Injection
Id Gender Age area CFU-F (%) hours Immuno-phenotype Adipo Osteo Myo Endo (passage) (passage)
hASCs-1 F 26 Abdomen 1.6 71.1 + O O O O 3 7
hASCs-2 F 58 Breast 1.4 69.0 + O O O O 4 8
hASCs-3 F 38 Abdomen 4.3 71.4 + O O O O 3 7
hASCs-4 F 31 Thigh/hip 0.6 120.2 + O O O O 4 8
hASCs-5 F 35 Abdomen 2.5 100.6 + O O O O 4 8
Clonogenic potential (CFU-F); proliferation rate expressed as doubling time (DT) calculated as t · ln(2)/ln(N/N0), where t is the duplication
time (h); N is the number of collected cells; and N0 is the number of plated cells. Immunephenotype characterizations performed by FACS
analysis and differentiation ability by functional test. Time spanning between cell thawing and hASCs injection for each population.
hASCs, human adipose-derived stem cells; CCI, chronic constriction injury.
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during the period of follow-up (Supplementary Table S1
Supplementary data; Supplementary Data are available on-
line at www.liebertpub.com/scd). Moreover, they did not
show any signs of macroscopic toxicity or behavioral change,
including food and water intake, so that the body weight
was stable in each group, and no significant differences were
observed between the weights registered at day 28 with re-
spect to the preadministration values in all the animal groups
(Supplementary Table S1 Supplementary data). Despite the
high number of mice we have injected (n > 60), death or
macroscopic toxicity was never observed, confirming that
MSCs derived from adipose tissue are neither toxic nor im-
munogenic.
Effect of hASCs on thermal hyperalgesia
and tactile allodynia in the sciatic nerve
CCI, a murine model of pain
A dose of hASCs, corresponding to 1· 106 cells, was ad-
ministered to mice intravenously 7 days after the CCI pro-
cedures, to allow pain chronicization. As shown in Fig. 2A,
B, the sciatic nerve constrictions provoked a significant re-
duction of the thermal withdrawal latency and mechanical
threshold, for hyperalgesia and allodynia, respectively, in the
CCI groups. hASCs treatment did not modify the pain
threshold in the sham group, whereas in the CCI group,
hASCs allowed mice to recover hyperalgesia scores compa-
rable to those of shammice already after 3 days, and the effect
was fully maintained at least until 7 days from injection. Al-
lodynia was also improved by hASCs injection, even if sig-
nificant differences between the CCI +hASCs and sham
groups persisted. Fromday 7, the pain reduction effect started
to progressively decrease, although scores remained signifi-
cantly better with respect to the CCI +vehicle group until day
21 from hASCs administration both for hyperalgesia and al-
lodynia (Fig. 2A, B). To more deeply assess the short-term
effect of 1 · 106 hASCs in CCI mice and to confirm the previ-
ous observations, we evaluated pain reduction in other mice
treated by another hASCs population (hASCs-5) focusing on
the antihyperalgesic and antiallodynic effect at 1, 3, and 7
days after injection (Fig. 2C, D): cell administration was able
to significantly increase hyperalgesia scores already 1 day
after treatment, and, as already observed in the previous ex-
periment, the effect lasted at least until day 7 (Fig. 2C). Also,
allodynia scores of the CCI +hASCs groupwere progressively
and significantly improved starting from day 1, although they
did not reach the same level of the sham mice (Fig. 2D).
Since we observed, during time, a progressive decrease of
the hASCs effect on pain reduction, we tested whether a
second cell dose was able to produce again the beneficial
FIG. 1. Human adipose-derived stem cell (hASCs) morphology, differentiation, and karyotype. Phase-contrast micropho-
tographs of hASCs cultured in control medium (CTRL) (A) and adipogenic, osteogenic, myogenic, and endothelial media (B)
(100 · magnification, bar represents 100mm); the differentiation time is indicated. (C) hASCs karyotyping by Q banding. (D)
hASCs cultured for 14 days in CTRL or adipogenic differentiation (ADIPO) media; phase-contrast images of cells fixed and
then stained by Oil Red O (200 · magnification; upper panel); hASCs maintained for 14 days in CTRL or osteogenic differ-
entiation (OSTEO) media and stained by Sirius Red (lower panel). (E) The % of increase of alkaline phosphatase (ALP) activity
and calcified extracellular matrix deposition for each osteodifferentiated hASCs population compared to CTRL cells are
indicated in the table. Values of ALP activity (left panel) and calcified extracellular matrix deposition (right panel) of undif-
ferentiated (CTRL, white bars) and osteogenic-differentiated (OSTEO, filled bars) hASCs for 14 and 21 days, respectively, are
shown in the lower graphs. Data are expressed as mean– SEM; ***P < 0.001 (n = 5).
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FIG. 2. Time course of the
effect of hASCs administered
intravenously (i.v.) 7 days after
injury to chronic constriction
injury (CCI) mice. Thermal
hyperalgesia (A, C, E, G) was
measured by plantar test and
mechanical allodynia (B, D, F,
H) by dynamic plantar esthe-
siometer, and the values
are expressed as seconds
and grams, respectively. CCI
group, sham group, CCI+
hASCs group, and sham+
hASCs group were formed
by 8–12 mice. A and B: Long-
lasting effect. Seven days after
surgery (time 0), mice received
a single dose of 1·106 hASCs,
and thresholds were measured
every week for 3 weeks after
treatment. C and D: Short-term
effect of hASCs treatment. Se-
ven days after surgery (time 0),
mice received a single dose of
1·106 hASCs, and thresholds
were measured 24h, 3 days,
and 7 days after cell adminis-
tration. (E, F) Seven days after
surgery (time 0) and 3 weeks
after the first administration
(time 21), mice received 2 dif-
ferent doses of 1· 106 hASCs/
each. (G, H) Seven days after
surgery (time 0) and 2 weeks
after the first administration
(time 14), mice received 2 dif-
ferent doses of 5· 105 hASCs/
each. Data represent means–
SEM of 8–12 mice. *P< 0.05,
**P< 0.01, ***P< 0.001 versus
sham+vehicle mice; P< 0.05,
P< 0.01, P< 0.001 versus
CCI+vehicle mice.
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effect. At first, 2 doses of 1· 106 cells were administered: one
after 7 days from CCI procedure and the other after further
21 days. The first cell injection caused a marked improve-
ment in the hyperalgesia test response, and when mice were
treated with a second dose, the analgesic effect was com-
pletely restored even if the mice were readministered when
the withdrawal latency was still significantly higher than the
lesioned mice (Fig. 2E). A similar trend was observed when
allodynia was evaluated; indeed, the second injection, per-
formed when the effect of the first one was not disappeared,
provoked a new slight improvement of the thresholds (Fig.
2F). Furthermore, to test the hASCs dose–response effect, we
treated another group of mice with a reduced number of cells
(5 · 105). The effect was less evident than the one previously
observed, due to the lower dose of hASCs; in particular, a
reduced effect and a more rapid return to the preinjection
level in comparison to the mice that had received 1· 106 cells
were noticed (Fig. 2G, H). For this reason, the second injec-
tion was administered just after 14 days from the first one
instead of 21 days as for the higher dose. Nevertheless, the
second treatment was comparable to the first one, suggesting
a dose–response relation (Fig. 2G, H).
Cytokine modulation by hASCs treatment
It is well known that CCI activates a neuroinflammatory
cascade characterized by the increase of proinflammatory
cytokines that play an important role in the etiopathogenesis
and maintenance of neuropathic pain. To verify an anti-
inflammatory or immunomodulatory action for hASCs-
mediated antiallodynic/antihyperalgesic mechanisms, we
checked inflammatory and anti-inflammatory cytokine levels
in the sciatic nerve. Fig. 3A shows that, as previously
reported by us and others [27,28,38], the levels of the
proinflammatory cytokine IL-1bwas significantly elevated in
sciatic nerves obtained from CCI animals. In 1· 106 hASCs-
treated animals, the IL-1b increase was already reverted 1
day after administration, and the effect was complete 3 days
later, as the IL-1b levels were similar to those of sham ani-
mals. Fig. 3B reports a decrease of the content of the anti-
inflammatory cytokine IL-10 after the lesion. The treatment
with 1· 106 hASCs was able to progressively restore the IL-
10 levels that 7 days after cell treatment appeared even more
elevated compared to those measured in sham animals. The
ability of hASCs to restore cytokine levels was dose depen-
dent: in fact, the injection of 5· 105 cells exerted a lower,
although still significant, effect on cytokine production (Fig.
3C, D). No hASCs significant effects on either IL-1b or IL-10
were observed in sham animals (data not shown). To un-
derstand whether hASCs secretion may contribute to the
cytokine increase, we also measured human IL-10 in the
same samples at all time points. In all groups, sciatic nerve
human IL-10 concentrations could not be detected in the
sciatic nerve (data not shown).
We evaluated murine IL-1b and IL-10 concentrations also
in the sera obtained 24 h and 7 days after hASCs adminis-
tration (Table 2). One day after hASCs administration, IL-1b
levels were significantly elevated in the CCI group in com-
parison to sham animals, and the treatment with hASCs did
not significantly modify IL-1b concentrations in any group.
At a later time point, no effect was still present. Low con-
centrations of IL-10 were detected in sera of all animal
groups, and no difference in CCI animals in comparison to
the sham ones was observed; however, we detected a sig-
nificant increase of IL-10 concentrations, 1 day after hASCs
injection, in both sera of sham and CCI animals. This increase
FIG. 3. Cytokine modulation
by hASCs treatment. Inter-
leukin (IL)-1b (A, C) and IL-10
(B, D) protein content in ipsi-
lateral sciatic nerve at different
days after i.v. administration
of 1· 106 (A, B) and 5 · 105 (C,
D) hASCs. Seven days after
surgery, hASCs were injected,
as in all experiments. Cytokine
protein content is normalized
to sample total protein. Data
are mean – SEM of 6–8 ani-
mals. *P < 0.05, **P < 0.01,
***P < 0.001 versus sham + ve-
hicle group at the correspond-
ing day; P < 0.05, P < 0.001
versus CCI +vehicle at the
corresponding day.
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was not detectable anymore after 7 days from hASCs ad-
ministration. We could not assay human cytokines in murine
sera (data not shown).
Spinal cord iNOS modulation by hASCs treatment
As shown in Fig. 4, 14 days after neuropathy induction,
the expression of iNOS in the ligated mouse spinal cord was
higher than in sham-operated animals, as expected. In the
CCI-hASCs-treated group, the expression of iNOS was
completely restored, indicating that the cells exert a relevant
action also in the central nervous system.
Discussion
This study demonstrated that intravenous injection of
human ASCs in a murine model of neuropathic pain (CCI
model) was able to relieve the induced hyperalgesia and
allodynia, in a dose-dependent manner; interestingly, re-
peated treatments produced a prolonged reduction of these
symptoms.
Recently, there has been a considerable evolution in the
comprehension of the mechanisms underlying the thera-
peutic effect of MSCs. The new evolving concept modifies
the implicit idea that the objective of the MSCs usefulness
was cell replacement therapy. Indeed, the recent literature
proposes the paracrine effect of MSCs, that is, cells exert their
effects by the release of factors that stimulate tissue recovery
at many potential levels, including stimulation of resident
stem/progenitor cells, remodeling of the extracellular matrix,
and stimulation of new blood vessel formation [39,40]. In the
last decade, MSCs-based therapies have been proposed as a
new possible scenario for neurodegenerative diseases, since
in vitro, they are able to adopt astrocytic- and neuronal-like
cell features [41], acquiring their specific morphological
characteristics, neural markers, and electrophysiological
properties [42]. However, in animals, they also seem to limit
damage or mediate repair of nervous tissue via mechanisms
other than cell replacement or transdifferentiation, that is, via
their paracrine function, releasing protective factors [43].
Among the neurodegenerative-related pathologies, neuro-
pathic pain is still classified as an incurable disease [44]. A
well-accepted hypothesis for the development of neuropathic
pain points to a nonphysiological repair of the damaged
nerve, resulting in the formation of neurinomas, deranged
nerve conduction, and generation of spontaneous firing. The
development of neuropathic pain involves not only neuronal
pathways but also components of the peripheral immune
system [45]. Inflammation, derived from the activation of
innate immune cells, is also present at the site of tissue injury.
These cells release immune-active substances, such as cyto-
kines, neurotrophic factors, and chemokines, which initiate
local actions and can result in a more generalized immune
response [46,47] and pain sensitization. There are many
studies documenting the pleiotropic effects of MSCs on the
immune system by both secreting bioactive molecules and
by cell–cell contact involving dendritic cells, B-, and T-cells
[48,49]. MSCs are known to show strong immunosuppres-
sive properties that can be exploited for successful autolo-
gous as well as heterologous transplantations without
requiring pharmacological immunosuppression [50,51]. In
our study, toxicity tests in immunocompetent mice demon-
strated the safety of intravenous injection of 1· 106, 3· 106,
and 6· 106 hASCs/mouse. No animal died or changed its
habits, and no side effects have been observed. The highest
dose of hASCs (2.4 · 108/kg body weight [b.w.]) corre-
sponds to the highest dose used in SCID mice by Ra et al.
[19]; moreover, lower doses of hASCs and BMSCs (2· 106/
mouse, corresponding to 8·107/kg body weight) have been
successfully used in previous studies in normal immunocom-
petent mice [52,53], confirming that human MSCs escape
Table 2. Mouse IL-1b and IL-10 Serum Concentration Measured 1 and 7 Days After hASCs Treatment
(8 and 14 Days After Lesion)
pg/mL serum Days Sham Sham + hASCs CCI CCI + hASCs
IL-1b 1 76.0 – 13.0 96– 8.2 167.1– 12.0* 145.1– 3.0*
IL-1b 7 46.8 – 16.0 67.3 – 18.7 74.0 – 24.0 53.0 – 14.4
IL-10 1 52.8 – 2.9 89.3 – 4.0* 53.9 – 1.2 67.2 – 3.5*
IL-10 7 54.4 – 3.7 61.3 – 8.4 54.8 – 5.9 52.9 – 3.0
Data are expressed as mean – SEM; *P< 0.05 versus sham animals (n= 6).
IL, interleukin.
FIG. 4. Induced nitric oxide synthase (iNOS) modulation.
iNOS content in the L4–L6 dorsal horn spinal cord 14 days
from lesion and 7 days after injection of 1 · 106 hASCs. iNOS
protein content was detected by western blot analysis. The
density mean value of the vehicle-injected sham-operated
mice within a single experiment was set to 100, and all the
other values were expressed as percentage versus the levels
detected in sham-operated mice. Each value represents
mean – SEM of 6–8 mice. *P< 0.05 versus sham + vehicle
group; P< 0.05 versus CCI + vehicle.
8 SACERDOTE ET AL.
immune system surveillance, probably since they do not
express HLA-DR [54], and so they are poorly recognized by T-
cells. It is known that adipose tissue represents an abundant
source of MSCs, and, for this reason, we used hASCs, believ-
ing that for the therapeutical purposes, large quantities of cells
must be produced by ex vivo expansion within a small
number of generations. All the hASCs populations which have
been tested, despite an expected physiological variability,
shared common features in vitro and produced very compa-
rable effects in our preclinical model of neuropathic pain.
Considering future clinical applications, and knowing that it
would be quite convenient to use cells on demand starting
from frozen stocks, here we utilized cryopreserved cells, at
early passages, cultured for about 2/3 weeks before i.v. in-
jection. A normal karyotype was maintained for at least 10 cell
generations after thawing, as it was previously shown by Ra
et al. [19] on fresh MSCs from adipose tissue, confirming the
potential safety of this approach.
hASCs systemic injection showed a very potent dose-
dependent antihyperalgesic effect. Low doses of hASCs
(5 · 105) partially reduced the pain symptoms for 14 days in
CCI mice, never reaching the level of sham animals. Com-
parable withdrawal latency and threshold values were ob-
served in our previous study when 2 · 106 murine NSCs
were injected i.v. in the same CCI model [27], thus suggest-
ing a more potent protective effect exerted by hASCs with
respect to murine NSCs. When CCI mice were treated with
1 · 106 hASCs i.v., a complete, rapid, and long-lasting re-
sponse was observed; indeed, hASCs effects on allodynia
and hyperalgesia were already fully achieved 24 h after their
administration: the hyperalgesia was completely controlled,
and allodynia was significantly reduced compared to the
CCI + vehicle-treated group. Moreover, the protective effect
was maintained for 21 days. Although not complete, the
entity of the effect on mechanical allodynia is of great rele-
vance, in consideration of the fact that this painful symptom
is particularly resistant to most analgesic treatments and
strategies [55,56].
Meantime, in a model of sciatic nerve-crush temporary
injury in mice, it has been recently shown that 2· 106 hASCs
accelerated the functional recovery in the treated mice with
respect to the placebo group [52]. Despite the fact that the
authors just tested 1 dose of hASCs, our data showed that
already low doses of hASCs may revert symptoms of neu-
ropathic pain, and that the hASCs effect can be boosted again
by repeating the administration of cell doses. We observed
that the period between the 2 administrations varied in
function of the number of injected cells: 5 · 105 cells required
a second administration after 14 days, whereas 1· 106 cells
showed a beneficial effect lasting for 21 days. Unfortunately,
we did not further prolong the experiment. For the future,
chronic treatments need to be planned to evaluate the pro-
tective effect at a longer follow-up.
Our data indicate that hASCs injected intravenously pos-
sess a rapid homing ability, since the peak of the anti-
hyperalgesic effect appears already in one day; this could be
due to the MSCs full repertoire of molecules that enable their
migration toward damaged tissues, allowing the researchers
to move from a local administration to a systemic one [52,53].
The presence of MSCs at the lesion site has been exten-
sively studied in several preclinical models; the results are
not always consistent, maybe due to the different methods of
detection with variable sensitivity. The number of traceable
cells seems to decrease over time, however. Marconi et al.
injected i.v. hASCs in a mouse model of sciatic crush, and
they detected human cells, responsible of both the improved
fiber sprouting and the reduction of the inflammatory infil-
trates at the nerve site 1 week after injection and 35 days
later [52].
Several studies address the influence of the route of cell
administration on the clinical or preclinical outcome. In the
regenerative field, ASCs have been shown to be able to en-
hance healing of mandibular defects in swine despite the
way of administrations [57]: cells injected both systemically
and locally into the defect completely repair the bone in 4
weeks, suggesting that a large number of ASCs reached and
remained in the lesioned area. Among the studies describing
the role of MSCs in pain relief, the elegant work of Guo et al.
[58] about hypersensitivity after tendon injury in a rat model
clearly shows that cells, injected i.v., act as the ones trans-
planted locally, suggesting that BMSCs act at the site of in-
jury. In addition, the authors showed that the observed
analgesic effect is both central and peripheral, and it seems
to be related to their stemness. In our study, we believe
that local and systemic hASCs are involved in the anti-
hyperalgesic effect, and at the moment, we do not figure out
which is the percentage of either circulating hASCs or re-
cruited cells at the lesion site responsible of the described
effect. Both cellular fractions might act synergistically; in-
deed, modulation of systemic endogenous cytokines is sug-
gested by the data included in Table 2. Studies indicating
that inflammation directs migration of transplanted MSCs to
the inflamed site are consistent as the data on the plethora of
molecules present on hASCs membrane able to affect their
homing behavior [59].
Although the mechanism of action of these cells is still not
completely elucidated, it is clear that the time course of the
effects on pain definitely anticipated any possible effect on
nerve repair, suggesting that their effect was likely due to
factors locally carried and/or secreted by hASCs and/or by
hASCs-stimulated resident cells, rather than a direct neu-
roregenerative action.
Indeed, hASCs are able to immediately downregulate, as
fast as 24 h after their administration, the sciatic nerve levels
of the proinflammatory cytokine IL-1b. Moreover, hASCs
administration triggers a slower, but progressive, increase of
the prototype anti-inflammatory cytokine IL-10, that, as
previously reported, is decreased by the neuropathic pa-
thology itself [27]. Seven days after hASCs administration,
IL-10 concentrations are 10-fold higher than those observed
in sciatic nerves obtained from neuropathic animals and 3
fold more elevated with respect to sham animals. This result
is well beyond what we observed with NSCs administration
and functionally very important. In fact it is now believed
that, the sensitizing role of proinflammatory cytokines on
pain transmission is one of the main components of the
generation of neuropathic pain over time [22,28], and that the
lack of a correct counterbalance response of anti-inflamma-
tory/inhibitory cytokines can underline maintenance of pain
[60]. Therefore, the IL-10 increase might explain the relevant
effect of hASCs on allodynia and hyperalgesia. We and
others demonstrated that the increase of proinflammatory
cytokines such as IL-1b and tumor necrosis factor (TNF)-a
well correlate with the presence of hyperalgesia and
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allodynia [61,62]. Moreover, when we previously tried to
treat experimental neuropathic pain with pharmacological
approaches, we always observed a parallelism between pain
and cytokine modulation [22,23,38]. However, the early
modulation of cytokines may induce/activate several en-
dogenous mechanisms that at later time sustained the anal-
gesic effect [52,53]. Consistently, the lower dose of hASCs
that was only partially effective on pain symptoms also
partially restored the normal cytokine levels. Indeed, we
observed a significant increase of IL-10 serum concentra-
tions, 1 day after hASCs treatment. These results suggest that
already at early time point after hASCs administration, con-
sistently with what reported by other groups [63–65], the
hASCs posses a systemic immunomodulatory and anti-
inflammatory activity that can blunt inflammatory cell in-
filtration and activation in the nervous tissue. However, the
local effect at the injured site seems to be more efficacious
and persistent, as demonstrated by the relevant suppression
induced by hASCs on nerve IL-1b production. Furthermore,
the known ability of MSCs to improve nerve blood flow by
secreting VEGF and bFGF, playing a crucial role in neo-
vascularization, might also be involved [16,66], together with
other specific biochemical factors delivered by hASCs, such
as glial cell-derived neurotrophic factor, IGF-1, brain-derived
neurotrophic factor, IL-6, TNF-a, TNF-stimulated gene 6
[67], and also bFGF, shown to be a neuroprotective factor
[68], which is able to improve sciatic nerve conduction in
streptozotocin-induced diabetic rats [69].
Several authors have suggested that the effect on MSCs
on hyperalgesia and allodynia could be sustained also by a
central effect [22,26,53]. The upregulation of iNOS expres-
sion in CCI mice is completely reverted 1 week after ad-
ministration of 106 hASCs, suggesting that systemic hASCs
affect pain transmission at the central level, and not just at
the lesion site, showing a modulation of iNOS at the level
of the spinal cord, indicating that hASCs can also modu-
late the spinal cord nociceptive signaling pathways. In fact,
we previously demonstrated that in CCI animals, the
neurons overexpressing iNOS are located in the lamina II,
specifically involved in pain transmission [22,23]. Based on
the previous results [27] and the present ones, injecting
hASCs, we feel confident in indicating both a local and
systemic effect by ASCs acting as both direct immuno-
modulators and modulators of the process of host cell
recruitment.
Here, we confirmed the rapid onset of hASCs effects,
which are dose-related and can be prolonged for an extended
period of time by recurrent treatments.
We conclude that the systemic administration of hASCs to
normal immunecompetent mice is safe, that high doses, at
least until 2.4 · 105 cells/g of b.w. are not toxic, and that
2 · 104 cells/g of b.w. are sufficient to promptly and com-
pletely revert neuropathic pain symptoms in a murine CCI
model. Moreover, their effects are more potent than those
elicited by murine NSCs, and we hypothesize that this dif-
ference can be due to the already-known relevant immuno-
modulatory potential of hASCs. The protection against
painful symptoms in CCI mice exerted by systemic admin-
istration of hASCs shown here might be more a consequence
of the paracrine action of mesenchymal progenitors that act
as a drug store, rather than just directly contribute to the
repair of the nerve injury [39].
Finally, the advantages of using hASCs rely on the large
number of cells that can be easily obtained from subcuta-
neous adipose tissue allowing autologous transplantations,
together with the absence of severe side effects. Therefore,
we suggest that hASCs are worthy of further study as a
valuable anti-inflammatory therapy in the treatment of
chronic pain or other neuroinflammatory diseases.
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